Presentations & Publications
Promising first-in-human, first-in-class, Phase 1b immunogenicity data of VRON-0200, a novel checkpoint modifier containing immunotherapy, for HBV functional cure
05/06/2024
Gane EJ, et al.
Poster –
EASL 2024, Poster # LBP-018